Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome (A.R.D.S) in Comparison to Interleukin 6 [IL-6]
1 other identifier
observational
60
0 countries
N/A
Brief Summary
In this prospective study of 60patients, we tested the hypothesis That markedly elevated levels of plasma von Willebrand factor (VWF) a marker of endothelial cell injury might predict the development of acute respiratory distress syndrome (A.R.D.S) in risky patients. We compared our result to IL.6 as control biomarker for A.R.D.S development. Acute lung injury was quantified on two -point scoring system (Berlin definition of ARDS and Murray score of acute lung injury). Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 18, 2020
CompletedStudy Start
First participant enrolled
March 21, 2020
CompletedFirst Posted
Study publicly available on registry
March 23, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 20, 2021
CompletedMarch 23, 2020
March 1, 2020
12 months
March 18, 2020
March 19, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
level of vwf at 72 hours
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
72 hours
Study Arms (2)
ARDS group ,
non ARDS group
Interventions
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
Eligibility Criteria
60 patients, admitted to the ICUs, staying \>24 hrs will be randomly assigned to enter this study.
You may qualify if:
- Patients between 18 and 80 years old of both sexes.
- risk factor for development of acute respiratory distress syndrome or acute lung injury either by:
- Direct lung injury includes: Severe pneumonia (infection), Breathing a vomited stomach contents (aspiration), Breathing harmful fumes or smoke, severe trauma to the chest or other accident that bruises the lungs.
- Indirect lung injury includes: sepsis, Severe injury or trauma with shock, blood transfusions , drug overdose acute pancreatitis, fracture of the long bones, near drowning ,anaphylaxis, uremia, fat embolus , and intracranial insult.
You may not qualify if:
- (1) pregnancy;
- (2) a preexisting medical condition with a life expectancy less than 3 months
- (3) evidence of cardiogenic pulmonary edema
- (4) age under 18 years old or above 80 years old
- (5) late stages of liver cell failure, renal failure
- (6) severe myocardial infarction
- (7) deep coma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant professor of anesthiology and ICU , faculty of medicine , Ain Shams univeristy
Study Record Dates
First Submitted
March 18, 2020
First Posted
March 23, 2020
Study Start
March 21, 2020
Primary Completion
March 20, 2021
Study Completion
September 20, 2021
Last Updated
March 23, 2020
Record last verified: 2020-03